Koneksa and Beacon Biosignals join forces on neuro biomarkers

Digital biomarkers company Koneksa and computational neurodiagnostics firm Beacon Biosignals have partnered to conduct a clinical trial to investigate the integration of Beacon’s at-home electroencephalogram (EEG) into Koneksa’s Neuroscience Solution Toolkit.

Beacon’s platform uses at-home EEG technology and applies machine-learning algorithms to provide insights into brain activity. The clinical validation study (called LEARNS) aims to discover biomarkers and determine the usability and validity of measures of sleep and neurologic disorders collected using at-home EEG, wearables, and smartphones.

The LEARNS study will compare the companies’ technologies with in-clinic polysomnography in determining biomarkers of neurological and sleep disorders. Conditions to be studied include Parkinson’s disease, narcolepsy, obstructive sleep apnea, Alzheimer’s disease, Huntington’s disease and mild cognitive impairment.

“The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO of Koneksa. “We’re on a mission to revolutionize drug development in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights. Our collaboration with Beacon Biosignals will enable sponsors to integrate our digital solutions into clinical trials to identify treatment signals earlier and faster than with traditional measures.”

The LEARNS study will measure the validity of smartphone-based motor, speech, and cognitive assessments versus gold-standard tools. The study will also evaluate whether assessment combinations can identify diagnostic features at the cohort diagnostic boundary.

“This opportunity will expand the reach of Beacon’s EEG-based precision neurodiagnostics to more sponsors, and will provide critical validation of methodology that we believe could be transformational to patients,” said Dr Christine Vietz, Chief Research and Development Officer at Beacon.